February 20, 2019, MedPage Today 

The goal of this study was to determine the safety and efficacy of umbilical cord blood (UCB) grafts using NiCord, a single cord blood unit expanded ex vivo with nicotinamide, and transplanted into patients with a variety of hematological malignancies after myeloablative conditioning. Researchers compared NiCord's activity to historical data on 146 closely-matched transplant patients from the Center for International Blood and Marrow Transplant Research (CIBMTR). 

Read more.